# Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study

> **NCT06888050** · PHASE4 · RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 268 (estimated)

## Conditions studied

- New-onset Type 2 Diabetes

## Interventions

- **DRUG:** henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06888050
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888050, "Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06888050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*